Literature DB >> 31840131

Subgrouping of Unfavorable Histology Neuroblastomas With Immunohistochemistry Toward Precision Prognosis and Therapy Stratification.

Naohiko Ikegaki1, Hiroyuki Shimada2.   

Abstract

Entities:  

Year:  2019        PMID： 31840131     DOI： 10.1200/PO.18.00312

Source DB:  PubMed          Journal:  JCO Precis Oncol        ISSN： 2473-4284


× No keyword cloud information.
  5 in total

1.  Clinical Relevance of CD4 Cytotoxic T Cells in High-Risk Neuroblastoma.

Authors:  Xao X Tang; Hiroyuki Shimada; Naohiko Ikegaki
Journal:  Front Immunol       Date:  2021-04-22       Impact factor: 7.561

Review 2.  Diagnosis and Management of Opsoclonus-Myoclonus-Ataxia Syndrome in Children: An International Perspective.

Authors:  Thomas Rossor; E Ann Yeh; Yasmin Khakoo; Paola Angelini; Cheryl Hemingway; Sarosh R Irani; Gudrun Schleiermacher; Paramala Santosh; Tim Lotze; Russell C Dale; Kumaran Deiva; Barbara Hero; Andrea Klein; Pedro de Alarcon; Mark P Gorman; Wendy G Mitchell; Ming Lim
Journal:  Neurol Neuroimmunol Neuroinflamm       Date:  2022-03-08

Review 3.  The Promise of Patient-Derived Preclinical Models to Accelerate the Implementation of Personalised Medicine for Children with Neuroblastoma.

Authors:  Elizabeth R Tucker; Sally George; Paola Angelini; Alejandra Bruna; Louis Chesler
Journal:  J Pers Med       Date:  2021-03-30

Review 4.  Genetic and Histopathological Heterogeneity of Neuroblastoma and Precision Therapeutic Approaches for Extremely Unfavorable Histology Subgroups.

Authors:  Hiroyuki Shimada; Naohiko Ikegaki
Journal:  Biomolecules       Date:  2022-01-05

5.  Prognostic Value of c-MYC Expression in Patients with Peripheral Neuroblastic Tumors.

Authors:  Feng Zhang; Zhuo Tian; Tinghong Li; Xianjun Hu; Jin Zhu
Journal:  Int J Gen Med       Date:  2021-06-28
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.